New medicines — urgent need to assess outcomes in special groups

Jennifer H Martin and Michael D Coory
Med J Aust 2012; 196 (7): . || doi: 10.5694/mja12.10193
Published online: 16 April 2012

A few achievable strategies could improve translation of clinical research to practice

Randomised controlled trials (RCTs) provide the most internally valid method of evaluating new pharmaceuticals and, appropriately, provide the core evidence for marketing approval. However, certain patient groups (eg, older people, young people, people with comorbidities, people taking concomitant medications) are typically excluded, and RCTs are often too small and their duration too short to detect uncommon but clinically important adverse drug reactions (ADRs). Consequently, the translation of these internally valid results to the real world of everyday clinical practice is not a trivial task.1

  • Jennifer H Martin1
  • Michael D Coory2

  • 1 Princess Alexandra Hospital and University of Queensland School of Medicine, Brisbane, QLD.
  • 2 Murdoch Childrens Research Institute, Melbourne, VIC.


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.